Presentation on theme: "Our Dana-Farber Experience Deirdre Foley & Matthew Murphy"— Presentation transcript:
1 Our Dana-Farber Experience Deirdre Foley & Matthew Murphy 2012 Student ResearchOur Dana-Farber ExperienceDeirdre Foley & Matthew Murphy
2 Our Dana-Farber Experience Dr O Gorman (MIRT Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston)Dr McCann – Student Summer Research Awards6-weeks student elective at DFCI – mixed clinical and research experience1. Multiple Myeloma out-patient clinics2. Oncology ward rounds at Brigham & Women’s hospital3. Shadowing researchers in Dr Anderson’s lab4. Development of own personal research projects
4 1. Analysis of Tumour Marker Expression, Karyotype and Cytogenetic Mutations in Patients with Multiple Myeloma at Dana-Farber Cancer Institute Matthew MurphyOur aim: To analyse the Tumour markers and Cytogenetic profiles of patients with MM at DFCI.Method: Data on 226 patient cohort with MM at DFCI collected. Analysis of the bone marrow aspirates taken for Flow Cytometry and Fluorescent In-situ Hybridisation (FISH) Cytogenetic Profiling was carried out.Results: Relative frequency of Tumour markers and Cytogenetic mutations seen in tables.Now that data has been collected for this specific cohort, collection of the patients’ circulating tumour cells (CTC) and analysis of the genetic mutations present in CTC will allow us to understand the pathology behind what makes MM cells metastasise.Of particular note a closer analysis of p53 mutation may be interesting to compare as previous data suggest that p53 is key to metastasis.
5 Flow Cytometry & FISH Studies - Results CONCLUSIONSFlow revealed a population of cells that were positive for:CDCDCyto-Kappa+ and Lambda+ (confirming mono-clonicity)FISH studies revealed that the most commonly affected genetic mutations within this cohort were:Trisomies of Chromosomes 3,7,9,11,15.Deletion of 14q32 was prevalent in 43% cases.Interestingly -17p otherwise known as p53 down-regulation was observed in 11.3% of cases. This corresponds to other finding from previous studies.
6 2. Occurrence of Extra-Medullary Disease in Multiple Myeloma – Analysis of a patient cohort at Dana Farber Cancer Institute Deirdre FoleyCollection of data from patient files (n=14)Focus on-1. PET-CT reports since diagnosis of Multiple Myeloma – EMD?2. Plain film radiographs – Lytic bone disease?3. Laboratory values at diagnosisHaemoglobinCreatinineSerum CalciumBeta-2 microglobulin.
7 Results-Radiograph of the skull demonstrating a typical lytic lesion in multiple myeloma –(http://emedicine.medscape.com/article/ overview )Most common sites of disease were Intra-abdominal and Sub-Cutaneous.Correlation between bony plasmacytomas, lytic bone disease, and severity of Extra-medullary diseaseView of plasmacytoma under microscopy -(http://en.wikipedia.org/wiki/Multiple_myeloma)
8 Our Dana-Farber Experience Educational experience - Multiple Myeloma and other haematological malignancies in a both clinical and lab based environmentNovel therapeutic agents – bench to bedside careImportance of international linksNecessity of research in medicineMedicine in an international setting - differences in practice in US v Ireland